Melane Sampson, Author at BioTuesdays

Developments

PharmaJet’s Tropis ID selected for Pakistan’s polio campaign

Closely held PharmaJet has announced that its WHO prequalified Tropis ID Needle-free Injection System will be used exclusively in Pakistan’s latest polio immunization campaign to deliver vaccines to 1.8 million children...

October 24, 2025

Developments

CorMedix receives innovative technology designation for DefenCath

CorMedix (NASDAQ: CRMD) has announced that its DefenCath antimicrobial catheter lock solution (CLS) has received innovative technology designation from closely held Vizient—a heathcare performance improvement company...

October 23, 2025

Developments

MAIA details exceptional survival in third-line NSCLC at ESMO

MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3...

October 23, 2025

Executive Moves

Three key appointments strengthen Amphista’s clinical development capabilities

Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio...

October 23, 2025

Developments

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve...

October 21, 2025

Developments

Tenon receives FDA 510(k) clearance for joint fusion system

Tenon Medical (NASDAQ:TNON) has announced that the FDA has granted 510(k) clearance for its SImmetry+ SI Joint Fusion System indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint...

October 21, 2025

Feature

In conversation with Dr. Tyler Evans, co-founder, CEO and CMO of Wellness Equity Alliance

Tyler B. Evans, MD, MS, MPH, is a leading voice in global health equity, infectious disease, and humanitarian medicine. As co-founder, CEO, and chief medical officer of Wellness Equity Alliance (WEA), Dr. Evans has...

October 21, 2025

Developments

USPTO publishes patent application for Clearmind’s MEAI for binge behavior disorders

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as...

October 20, 2025

Developments

Profound congratulates Busch Center for 500th TULSA procedure achieved

Profound Medical (NASDAQ: PROF; TSX: PRN) has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and...

October 16, 2025

Developments

Theravance launches education campaign for nOH associated with MSA

Theravance Biopharma (NASDAQ: TBPH) has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic...

October 16, 2025

Author - Melane Sampson

PharmaJet’s Tropis ID selected for Pakistan’s polio campaign

CorMedix receives innovative technology designation for DefenCath

MAIA details exceptional survival in third-line NSCLC at ESMO

Three key appointments strengthen Amphista’s clinical development capabilities

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Tenon receives FDA 510(k) clearance for joint fusion system

In conversation with Dr. Tyler Evans, co-founder, CEO and CMO of Wellness Equity Alliance

USPTO publishes patent application for Clearmind’s MEAI for binge behavior disorders

Profound congratulates Busch Center for 500th TULSA procedure achieved

Theravance launches education campaign for nOH associated with MSA

Subscribe